Concurrent Investment Advisors LLC purchased a new stake in shares of Tilray Inc (NASDAQ:TLRY – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 62,397 shares of the company’s stock, valued at approximately $110,000.
Several other hedge funds have also modified their holdings of TLRY. Tidal Investments LLC grew its stake in shares of Tilray by 36,687.0% during the first quarter. Tidal Investments LLC now owns 10,677,428 shares of the company’s stock valued at $26,373,000 after purchasing an additional 10,648,403 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Tilray by 19.6% during the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock valued at $3,622,000 after purchasing an additional 355,778 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Tilray during the first quarter valued at approximately $586,000. J.W. Cole Advisors Inc. grew its stake in shares of Tilray by 1,077.2% during the second quarter. J.W. Cole Advisors Inc. now owns 171,054 shares of the company’s stock valued at $284,000 after purchasing an additional 156,524 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft boosted its stake in Tilray by 103.1% in the second quarter. Baader Bank Aktiengesellschaft now owns 304,582 shares of the company’s stock valued at $504,000 after acquiring an additional 154,582 shares during the last quarter. 9.35% of the stock is owned by institutional investors.
Tilray Price Performance
Shares of TLRY stock opened at $1.47 on Wednesday. Tilray Inc has a 52-week low of $1.36 and a 52-week high of $2.97. The stock has a market cap of $1.33 billion, a PE ratio of -5.44 and a beta of 2.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47. The firm’s 50 day moving average price is $1.66 and its two-hundred day moving average price is $1.78.
Analyst Ratings Changes
Separately, Roth Mkm reduced their price objective on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, October 11th.
Check Out Our Latest Research Report on Tilray
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
See Also
- Five stocks we like better than Tilray
- ESG Stocks, What Investors Should Know
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What is Put Option Volume?
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Inc (NASDAQ:TLRY – Free Report).
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.